Clinical trialNCT05999240RecruitingPhase 2Interventional

Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder

SponsorNew York State Psychiatric InstituteEnrollment30Autism Spectrum Disorder

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This Phase 2 study examines the safety, tolerability, and preliminary efficacy of pimavanserin in individuals with Autism Spectrum Disorder. Male or female participants aged 12 to 40 years of age will be randomized to receive single doses of either placebo or pimavanserin in this randomized, placebo-controlled, cross-over designed study, followed by open label extension.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Jeremy Veenstra-VanderWeele, MD
New York State Psychiatric Institute
Principal Investigator
clinicaltrials.gov ↗
Matthew Mosconi, PhD
University of Kansas Center for Autism Research and Training
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Kansas, Center for Research
Lawrence, Kansas, United States
Ann Genovese, MDMatt Mosconi, PhDRobin Shafer, PhD
Recruiting
Center for Autism and the Developing Brain
White Plains, New York, United States
Jeremy Veenstra-VanderWeele, MDKaren Tang, PhDPankhuree Vandana, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Pimavanserin →Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 1 Oct 2025
Primary completion: 31 Dec 2026
Completion: 31 Dec 2026
Last update posted: 1 Apr 2026
Registered enrollment: 30
Registry id: NCT05999240

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.